NYXH

Nyxoah SA is a healthcare company within the medical instruments and supplies industry. With a market capitalization of $202.22 million, the company has a relatively small scale compared to its peers in the sector. Its revenue stands at $5.64 million (TTM), while it employs 183 people. The company's financial health is concerning, with significant net losses and negative returns on equity and assets. The operating margin is -1235.8%, indicating substantial operational expenses. The debt-to-equity ratio of 41.53 suggests a relatively high level of leverage. However, the cash balance stands at $22.48 million, which may provide some buffer against short-term liabilities. The valuation context for Nyxoah SA is challenging, with a negative forward P/E ratio of -1.81 and an EV/EBITDA ratio of -2.04. The price-to-sales ratio is 35.86, suggesting that the stock's value is significantly influenced by its revenue growth rate, which stands at 55.8% (YoY). Notably, the company does not pay dividends, with a payout ratio of 0.0%.